Current understanding of how immunodeficiencies impact protective responses against viral infections and vaccination is primarily derived from adult cohorts that may not accurately reflect the pediatric, adolescent, and young adult population. This cross-sectional study aimed to evaluate immune responses in this underrepresented population affected by various immunodeficiencies after SARS-CoV-2 infection, two doses of the mRNA BNT162b2 vaccine, or after a combination of both. We analyzed blood samples from 102 immunocompromised patients (IC) (5-25 years) categorized into groups of primary immunodeficiencies (PID, n=17), bronchial asthma and allergic rhinitis (BA-AR, n=39), rheumatoid diseases (RD, n=21), and individuals who had undergone hematopoietic stem cell transplantation (HSCT, n=28), as well as 30 healthy individuals (9-26 years). We measured titres of Spike-specific IgM, IgA, and IgG antibody classes (including IgG subclasses) in plasma using ELISA and evaluated their inhibitory potential in a Spike-ACE2 cell-based internalization assay. Spike-specific CD4 T-cells were examined using a flow cytometry-based proliferation assay (FASCIA). In the IC group, all participants except eight generated detectable levels of IgG antibodies. The IgG titres induced by vaccination (Geometric mean titre (GMTvac) = 205023, 95% CI: 116074-362136) and a combination of vaccination and infection (GMThyb = 172819, 95% CI: 33133-901403) were higher than after infection (GMTinf = 3323, 95% CI: 578-19109, Pvac/inf = .006 and Phyb/inf = .001). On the other hand, the hybrid immunity induced the highest IgA titres (GMThyb = 2672, 95% CI: 566-12623) compared to vaccination (GMPvac = 275, 95% CI: 97-777, Phyb/vac = .016) and infection (GMTinf = 60, 95% CI: 13-280, Phyb/inf = .002). The IgG titres in vaccinated and hybrid immunity groups strongly correlated (rSpearman = 0.86, P <.0001) with the levels of antibodies inhibiting the internalization of Spike protein (S protein) in a cell-based assay. Most IC patients (except five) also developed above-threshold Spike-specific CD4 T-cell responses, which were not statistically different from the responses in the healthy control group. Our data show that infection and vaccination can induce protective humoral or cellular responses against SARS-CoV-2 in IC patients. The activated cellular response in patients with agammaglobulinemia may assist them in overcoming viral infections.

AXON Neuroscience R and D Services SE Bratislava Slovakia

Department of Paediatric Haematology and Oncology National Institute of Children's Diseases Bratislava Slovakia

Department of Paediatric Medical Faculty Comenius University in Bratislava Bratislava Slovakia

Department of Paediatric National Institute of Children's Diseases Bratislava Slovakia

Faculty of Science Institute of Mathematics and Statistics Masaryk University Brno Czechia

Institute of Neuroimmunology Slovak Academy of Sciences Bratislava Slovakia

Zobrazit více v PubMed

Shields AM, Burns SO, Savic S, Richter AG, Consortium UPC . COVID-19 in patients with primary and secondary immunodeficiency: The United Kingdom experience. J Allergy Clin Immunol. (2021) 147:870–5 e1. doi:  10.1016/j.jaci.2020.12.620, PMID: PubMed DOI PMC

Poli MC, Aksentijevich I, Bousfiha AA, Cunningham-Rundles C, Hambleton S, Klein C, et al. Human inborn errors of immunity: 2024 update on the classification from the International Union of Immunological Societies Expert Committee. J Hum Immun. (2025) 1(1):e20250003. doi:  10.70962/jhi.20250003, PMID: DOI

Jeong S, Lee N, Lee SK, Cho EJ, Hyun J, Park MJ, et al. Humoral and cellular responses to BNT162b2 as a booster following two doses of chAdOx1 nCov-19 determined using three SARS-coV-2 antibody assays and an interferon-gamma release assay: A prospective longitudinal study in healthcare workers. Front Immunol. (2022) 13:859019. doi:  10.3389/fimmu.2022.859019, PMID: PubMed DOI PMC

Mahrokhian SH, Tostanoski LH, Vidal SJ, Barouch DH. COVID-19 vaccines: Immune correlates and clinical outcomes. Hum Vaccin Immunother. (2024) 20:2324549. doi:  10.1080/21645515.2024.2324549, PMID: PubMed DOI PMC

Bylica I, Jachowicz-Matczak E, Brodowicz J, Sulkowska J, Bociaga-Jasik M, Heczko P, et al. SARS-coV-2 vaccine-induced humoral immunity in immunocompetent european adults: A systematic review. Microorganisms. (2025) 13(3):535. doi:  10.3390/microorganisms13030535, PMID: PubMed DOI PMC

Gaultier GN, McMillan B, Poloni C, Lo M, Cai B, Zheng JJ, et al. Adaptive immune responses to two-dose COVID-19 vaccine series in healthy Canadian adults >/= 50 years: a prospective, observational cohort study. Sci Rep. (2024) 14:8926. doi:  10.1038/s41598-024-59535-0, PMID: PubMed DOI PMC

Srivastava K, Carreno JM, Gleason C, Monahan B, Singh G, Abbad A, et al. SARS-CoV-2-infection- and vaccine-induced antibody responses are long lasting with an initial waning phase followed by a stabilization phase. Immunity. (2024) 57:587–99 e4. doi:  10.1016/j.immuni.2024.01.017, PMID: PubMed DOI PMC

Hagin D, Freund T, Navon M, Halperin T, Adir D, Marom R, et al. Immunogenicity of Pfizer-BioNTech COVID-19 vaccine in patients with inborn errors of immunity. J Allergy Clin Immunol. (2021) 148:739–49. doi:  10.1016/j.jaci.2021.05.029, PMID: PubMed DOI PMC

van Leeuwen LPM, GeurtsvanKessel CH, Ellerbroek PM, de Bree GJ, Potjewijd J, Rutgers A, et al. Immunogenicity of the mRNA-1273 COVID-19 vaccine in adult patients with inborn errors of immunity. J Allergy Clin Immunol. (2022) 149:1949–57. doi:  10.1016/j.jaci.2022.04.002, PMID: PubMed DOI PMC

Gutierrez-Bautista JF, Diaz-Alberola I, Tarrino M, Aguilera M, Cobo F, Reguera JA, et al. Follow-up of immune response in patients with common variable immunodeficiency following SARS-CoV-2 vaccination. Clin Exp Immunol. (2024) 217:253–62. doi:  10.1093/cei/uxae039, PMID: PubMed DOI PMC

Olivieri G, Amodio D, Manno EC, Santilli V, Cotugno N, Palma P. Shielding the immunocompromised: COVID-19 prevention strategies for patients with primary and secondary immunodeficiencies. Vaccine. (2025) 51:126853. doi:  10.1016/j.vaccine.2025.126853, PMID: PubMed DOI

van Leeuwen LPM, Grobben M, GeurtsvanKessel CH, Ellerbroek PM, de Bree GJ, Potjewijd J, et al. Immunogenicity of COVID-19 booster vaccination in IEI patients and their one year clinical follow-up after start of the COVID-19 vaccination program. Front Immunol. (2024) 15:1390022. doi:  10.3389/fimmu.2024.1390022, PMID: PubMed DOI PMC

Di Chiara C, Cantarutti A, Costenaro P, Dona D, Bonfante F, Cosma C, et al. Long-term immune response to SARS-coV-2 infection among children and adults after mild infection. JAMA Netw Open. (2022) 5:e2221616. doi:  10.1001/jamanetworkopen.2022.21616, PMID: PubMed DOI PMC

Di Chiara C, Cantarutti A, Raffaella Petrara M, Bonfante F, Benetti E, Boracchini R, et al. Stronger and durable SARS-CoV-2 immune response to mRNA vaccines in 5–11 years old children with prior COVID-19. Vaccine. (2024) 42:263–70. doi:  10.1016/j.vaccine.2023.12.006, PMID: PubMed DOI

Petrara MR, Bonfante F, Costenaro P, Cantarutti A, Carmona F, Ruffoni E, et al. Asymptomatic and mild SARS-coV-2 infections elicit lower immune activation and higher specific neutralizing antibodies in children than in adults. Front Immunol. (2021) 12:741796. doi:  10.3389/fimmu.2021.741796, PMID: PubMed DOI PMC

Kovacech B, Fialova L, Filipcik P, Skrabana R, Zilkova M, Paulenka-Ivanovova N, et al. Monoclonal antibodies targeting two immunodominant epitopes on the Spike protein neutralize emerging SARS-CoV-2 variants of concern. EBioMedicine. (2022) 76:103818. doi:  10.1016/j.ebiom.2022.103818, PMID: PubMed DOI PMC

Egri N, Olive V, Hernandez-Rodriguez J, Castro P, De Guzman C, Heredia L, et al. CoVITEST: A fast and reliable method to monitor anti-SARS-coV-2 specific T cells from whole blood. Front Immunol. (2022) 13:848586. doi:  10.3389/fimmu.2022.848586, PMID: PubMed DOI PMC

Marits P, Wikstrom AC, Popadic D, Winqvist O, Thunberg S. Evaluation of T and B lymphocyte function in clinical practice using a flow cytometry based proliferation assay. Clin Immunol. (2014) 153:332–42. doi:  10.1016/j.clim.2014.05.010, PMID: PubMed DOI

Team TRC . R: A language and environment for statistical computing. R Foundation; (2024). Version 4.4.3 (2025-02-28). Available online at: https://cran.r-project.org.

Efron B, Tibshirani R. An introduction to the bootstrap Vol. xvi. . New York: Chapman & Hall; (1993). p. 436.

Best DJ, Roberts DE. Algorithm AS 89: the upper tail probabilities of spearman’s rho. J R Stat Soc Ser C Appl Stat. (1975) 24:377–9. doi:  10.2307/2347111 DOI

Weis D, Lin LL, Wang HH, Li ZJ, Kusikova K, Ciznar P, et al. Biallelic Cys141Tyr variant of SEL1L is associated with neurodevelopmental disorders, agammaglobulinemia, and premature death. J Clin Invest. (2024) 134(2):e170882. doi:  10.1172/JCI170882, PMID: PubMed DOI PMC

Fernandez-Moreno R, Valle-Arroyo J, Paez-Vega A, Salinas A, Cano A, Perez AB, et al. Memory SARS-CoV-2 T-cell response in convalescent COVID-19 patients with undetectable specific IgG antibodies: a comparative study. Front Immunol. (2023) 14:1142918. doi:  10.3389/fimmu.2023.1142918, PMID: PubMed DOI PMC

Lind Enoksson S, Bergman P, Klingstrom J, Bostrom F, Da Silva Rodrigues R, Winerdal ME, et al. A flow cytometry-based proliferation assay for clinical evaluation of T-cell memory against SARS-CoV-2. J Immunol Methods. (2021) 499:113159. doi:  10.1016/j.jim.2021.113159, PMID: PubMed DOI PMC

Lafon E, Jager M, Bauer A, Reindl M, Bellmann-Weiler R, Wilflingseder D, et al. Comparative analyses of IgG/IgA neutralizing effects induced by three COVID-19 vaccines against variants of concern. J Allergy Clin Immunol. (2022) 149:1242–52 e12. doi:  10.1016/j.jaci.2022.01.013, PMID: PubMed DOI PMC

de Gier B, Huiberts AJ, Hoeve CE, den Hartog G, van Werkhoven H, van Binnendijk R, et al. Effects of COVID-19 vaccination and previous infection on Omicron SARS-CoV-2 infection and relation with serology. Nat Commun. (2023) 14:4793. doi:  10.1038/s41467-023-40195-z, PMID: PubMed DOI PMC

Lu LL, Suscovich TJ, Fortune SM, Alter G. Beyond binding: antibody effector functions in infectious diseases. Nat Rev Immunol. (2018) 18:46–61. doi:  10.1038/nri.2017.106, PMID: PubMed DOI PMC

Shiakolas AR, Kramer KJ, Wrapp D, Richardson SI, Schafer A, Wall S, et al. Cross-reactive coronavirus antibodies with diverse epitope specificities and Fc effector functions. Cell Rep Med. (2021) 2:100313. doi:  10.1016/j.xcrm.2021.100313, PMID: PubMed DOI PMC

Zhang A, Stacey HD, D’Agostino MR, Tugg Y, Marzok A, Miller MS. Beyond neutralization: Fc-dependent antibody effector functions in SARS-CoV-2 infection. Nat Rev Immunol. (2023) 23:381–96. doi:  10.1038/s41577-022-00813-1, PMID: PubMed DOI PMC

Vidarsson G, Dekkers G, Rispens T. IgG subclasses and allotypes: from structure to effector functions. Front Immunol. (2014) 5:520. doi:  10.3389/fimmu.2014.00520, PMID: PubMed DOI PMC

Aalberse RC, Dieges PH, Knul-Bretlova V, Vooren P, Aalbers M, van Leeuwen J. IgG4 as a blocking antibody. Clin Rev Allergy. (1983) 1:289–302. doi:  10.1007/BF02991163, PMID: PubMed DOI

Lindahl H, Chen P, Aberg M, Ljunggren HG, Buggert M, Aleman S, et al. SARS-coV-2 antibodies in commercial immunoglobulin products show markedly reduced cross-reactivities against omicron variants. J Clin Immunol. (2023) 43:1075–82. doi:  10.1007/s10875-023-01486-8, PMID: PubMed DOI PMC

Nielsen BU, Drabe CH, Barnkob MB, Johansen IS, Hansen AKK, Nilsson AC, et al. Antibody response following the third and fourth SARS-CoV-2 vaccine dose in individuals with common variable immunodeficiency. Front Immunol. (2022) 13:934476. doi:  10.3389/fimmu.2022.934476, PMID: PubMed DOI PMC

Noto A, Cassin R, Mattiello V, Bortolotti M, Reda G, Barcellini W. Should treatment of hypogammaglobulinemia with immunoglobulin replacement therapy (IgRT) become standard of care in patients with chronic lymphocytic leukemia? Front Immunol. (2023) 14:1062376. doi:  10.3389/fimmu.2023.1062376, PMID: PubMed DOI PMC

van Leeuwen LPM, Grobben M, GeurtsvanKessel CH, Ellerbroek PM, de Bree GJ, Potjewijd J, et al. Immune responses 6 months after mRNA-1273 COVID-19 vaccination and the effect of a third vaccination in patients with inborn errors of immunity. J Clin Immunol. (2023) 43:1104–17. doi:  10.1007/s10875-023-01514-7, PMID: PubMed DOI PMC

Irrgang P, Gerling J, Kocher K, Lapuente D, Steininger P, Habenicht K, et al. Class switch toward noninflammatory, spike-specific IgG4 antibodies after repeated SARS-CoV-2 mRNA vaccination. Sci Immunol. (2023) 8:eade2798. doi:  10.1126/sciimmunol.ade2798, PMID: PubMed DOI PMC

Garcia-Basteiro AL, Moncunill G, Tortajada M, Vidal M, Guinovart C, Jimenez A, et al. Seroprevalence of antibodies against SARS-CoV-2 among health care workers in a large Spanish reference hospital. Nat Commun. (2020) 11:3500. doi:  10.1038/s41467-020-17318-x, PMID: PubMed DOI PMC

Noval MG, Kaczmarek ME, Koide A, Rodriguez-Rodriguez BA, Louie P, Tada T, et al. Antibody isotype diversity against SARS-CoV-2 is associated with differential serum neutralization capacities. Sci Rep. (2021) 11:5538. doi:  10.1038/s41598-021-84913-3, PMID: PubMed DOI PMC

Tan W, Lu Y, Zhang J, Wang J, Dan Y, Tan Z, et al. Viral kinetics and antibody responses in patients with COVID-19. medRxiv preprint. (2020). doi:  10.1101/2020.03.24.20042382 DOI

Egri N, Calderon H, Martinez R, Vazquez M, Gomez-Caverzaschi V, Pascal M, et al. Cellular and humoral responses after second and third SARS-CoV-2 vaccinations in patients with autoimmune diseases treated with rituximab: specific T cell immunity remains longer and plays a protective role against SARS-CoV-2 reinfections. Front Immunol. (2023) 14:1146841. doi:  10.3389/fimmu.2023.1146841, PMID: PubMed DOI PMC

Gao Y, Cai C, Wullimann D, Niessl J, Rivera-Ballesteros O, Chen P, et al. Immunodeficiency syndromes differentially impact the functional profile of SARS-CoV-2-specific T cells elicited by mRNA vaccination. Immunity. (2022) 55:1732–46 e5. doi:  10.1016/j.immuni.2022.07.005, PMID: PubMed DOI PMC

Russo C, Otero A, Uranga M, Seery V, Raiden S, Algieri S, et al. Immunological memory to COVID-19 vaccines in immunocompromised and immunocompetent children. Front Cell Infect Microbiol. (2025) 15:1527573. doi:  10.3389/fcimb.2025.1527573, PMID: PubMed DOI PMC

Vossen MG, Kartnig F, Mrak D, Simader E, Stiasny K, Kain R, et al. Humoral and cellular response to the third COVID-19 vaccination in patients with inborn errors of immunity or mannose-binding lectin deficiency: A prospective controlled open-label trial. Wien Klin Wochenschr. (2024) 136:598–607. doi:  10.1007/s00508-024-02459-6, PMID: PubMed DOI PMC

Erra L, Uriarte I, Colado A, Paolini MV, Seminario G, Fernandez JB, et al. COVID-19 vaccination responses with different vaccine platforms in patients with inborn errors of immunity. J Clin Immunol. (2023) 43:271–85. doi:  10.1007/s10875-022-01382-7, PMID: PubMed DOI PMC

Murray CE, O’Brien C, Alamin S, Phelan SH, Argue R, Kiersey R, et al. Cellular and humoral immunogenicity of the COVID-19 vaccine and COVID-19 disease severity in individuals with immunodeficiency. Front Immunol. (2023) 14:1131604. doi:  10.3389/fimmu.2023.1131604, PMID: PubMed DOI PMC

Salinas AF, Mortari EP, Terreri S, Quintarelli C, Pulvirenti F, Di Cecca S, et al. SARS-coV-2 vaccine induced atypical immune responses in antibody defects: everybody does their best. J Clin Immunol. (2021) 41:1709–22. doi:  10.1007/s10875-021-01133-0, PMID: PubMed DOI PMC

Sette A, Crotty S. Adaptive immunity to SARS-coV-2 and COVID-19. Cell. (2021) 184:861–80. doi:  10.1016/j.cell.2021.01.007, PMID: PubMed DOI PMC

Braun J, Loyal L, Frentsch M, Wendisch D, Georg P, Kurth F, et al. SARS-CoV-2-reactive T cells in healthy donors and patients with COVID-19. Nature. (2020) 587:270–4. doi:  10.1038/s41586-020-2598-9, PMID: PubMed DOI

Zhao J, Zhao J, Mangalam AK, Channappanavar R, Fett C, Meyerholz DK, et al. Airway memory CD4(+) T cells mediate protective immunity against emerging respiratory coronaviruses. Immunity. (2016) 44:1379–91. doi:  10.1016/j.immuni.2016.05.006, PMID: PubMed DOI PMC

Soresina A, Moratto D, Chiarini M, Paolillo C, Baresi G, Foca E, et al. Two X-linked agammaglobulinemia patients develop pneumonia as COVID-19 manifestation but recover. Pediatr Allergy Immunol. (2020) 31:565–9. doi:  10.1111/pai.13263, PMID: PubMed DOI PMC